

NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHSScotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and preferences.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultation with healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines included, which are consistent across the health board.

How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland
 - how well the medicine works,
 - which patients might benefit from it,
 - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
 - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence (NICE) appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

Why is a particular medicine not routinely available in NHSGG&C?

- This is usually because the medicine is not recommended for use in NHSScotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences in which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

Medicine	Condition being treated	NHSGGC Decision	Date of decision
----------	-------------------------	-----------------	------------------

birch bark extract	0 treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/10/2024	19/08/2024
Filsuvez®			
SMC2651			
dasatinib	0 Treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) integrated with chemotherapy	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/10/2024	19/08/2024
NCMAG116			
dasatinib	0 Dasatinib for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/10/2002	19/08/2024
NCMAG117			
dostarlimab	0 In combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.	Routinely available in line with local or regional guidance	19/08/2024
Jemperli®			
SMC2635			
empagliflozin	0 For the treatment of CKD in adults	Routinely available in line with local or regional guidance	19/08/2024
Jardiance®			
SMC2642			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
epcoritamab Tepkinly® SMC2632	0 Monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/10/2024	19/08/2024
Esketamine Spravato® SMC2258	0 In combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI), for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.	Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative	19/08/2024
etranacogene dezaparvovec Hemgenix® SMC2649	0 treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/10/2024	19/08/2024
fezolinetant Veozza® SMC2702	0 Treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.	Not routinely available as not recommended for use in NHSScotland	19/08/2024

Medicine	Condition being treated	NHSGGC Decision	Date of decision
follitropin delta Rekovel® SMC2670	0 Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/10/2024	19/08/2024
glofitamab Columvi® SMC2614	0 Monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/10/2024	19/08/2024
ivosidenib Tibsovo® SMC2615	0 In combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy.	Routinely available in line with local or regional guidance	19/08/2024
lenacapavir Sunlenca® SMC2691	0 Film-coated tablets: in combination with other antiretroviral(s) for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen, for oral loading prior to administration of long-acting lenacapavir injection Solution for injection: in combination with other antiretroviral(s) for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen..	Not routinely available as not recommended for use in NHSScotland	19/08/2024

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p>Loncastuximab tesirine</p> <p>Zynlonta®</p> <p>SMC2609</p>	<p>monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy</p>	<p>Routinely available in line with local or regional guidance</p>	<p>19/08/2024</p>
<p>mavacamten</p> <p>Camzyos®</p> <p>SMC2618</p>	<p>Treatment of symptomatic (New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.</p>	<p>Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/10/2024</p>	<p>19/08/2024</p>
<p>momelotinib</p> <p>Omjjara®</p> <p>SMC2636</p>	<p>Treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.</p>	<p>Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/10/2024</p>	<p>19/08/2024</p>
<p>nivolumab</p> <p>Opdivo®</p> <p>SMC2704</p>	<p>Adjuvant treatment of adults and adolescents 12 years of age and older with Stage IIB or IIC melanoma</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>19/08/2024</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
nivolumab, relatlimab Opdualag® SMC2645	0 First-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/10/2024	19/08/2024
olaparib Lynparza® SMC2617	0 In combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.	Routinely available in line with local or regional guidance	19/08/2024
pegunigalsidase alfa Elfabrio® SMC2665	0 for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/10/2024	19/08/2024
pembrolizumab Keytruda® SMC2644	0 in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS \geq 1.	Not routinely available as not recommended for use in NHSScotland	19/08/2024

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p>pembrolizumab</p> <p>Keytruda®</p> <p>SMC2660</p>	<p>in combination with fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express programmed death-ligand 1 (PD-L1) with a combined positive score (CPS) ≥ 1.</p>	<p>Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/10/2024</p>	<p>19/08/2024</p>
<p>pembrolizumab</p> <p>Keytruda®</p> <p>SMC2589</p>	<p>As monotherapy for adults with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in the following settings:</p> <ul style="list-style-type: none"> - treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine-based combination therapy. <p>As monotherapy for the treatment of the following MSI-H or dMMR tumours in adults with:</p> <ul style="list-style-type: none"> - advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation; - unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. 	<p>Routinely available in line with local or regional guidance</p>	<p>19/08/2024</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
remdesivir	treatment of COVID-19 in: 0 - adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).	Routinely available in line with local or regional guidance	19/08/2024
Veklury®			
SMC2550	- adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19		
remimazolam	0 Adults for intravenous induction and maintenance of general anaesthesia.	Not routinely available as not recommended for use in NHSScotland	19/08/2024
Byfavo®			
SMC2692			
Semaglutide	0 An adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:	19/08/2024
Wegovy	• ≥ 30 kg/m ² (obesity), or		
SMC2497	• ≥ 27 kg/m ² to < 30 kg/m ² (overweight) in the presence of at least one weight-related comorbidity.	09/12/2024	

Medicine	Condition being treated	NHSGGC Decision	Date of decision
talazoparib Talzena® SMC2607	0 Monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.	Routinely available in line with local or regional guidance	19/08/2024
talquetamab Talvey® SMC2705	0 Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy	Not routinely available as not recommended for use in NHSScotland	19/08/2024
tirzepatide Mounjaro® SMC2653	0 For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥ 30 kg/m ² (obesity) or ≥ 27 kg/m ² to < 30 kg/m ² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 09/12/2024	19/08/2024

Medicine	Condition being treated	NHSGGC Decision	Date of decision
trastuzumab deruxtecan Enhertu® SMC2706	0 Monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.	Not routinely available as not recommended for use in NHSScotland	19/08/2024
trastuzumab deruxtecan Enhertu® SMC2693	0 Monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.	Not routinely available as not recommended for use in NHSScotland	19/08/2024
trifluridine, tipiracil Lonsurf® SMC2654	0 In combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 07/10/2024	19/08/2024
voretigene neparvovec Luxturna® SMC2641	0 Treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.	Routinely available from a specialist centre in another health board	19/08/2024